• Provide executive oversight of day-to-day operations at Corporate HQ in Sunnyvale, CA.• Manage all day-to-day financial operations and close processes.• Oversee the Financial, Planning and Analysis function. • Manage the company’s SEC filings, including the writing of the Management Discussion and Analysis (“MD&A”) and Business sections for the Forms 10-Q and 10-K.• Quarterly presentations/communications to the Board of Directors (“BOD”) and Committees of the Board.• Manage the evaluation of internal controls through outsourced internal audit and facilitated the remediation of identified control deficiencies in support of Sarbanes-Oxley Section 404 (“SOX”) requirements.• Manage the 3rd party tax providers, including quarterly & annual provisions and federal & state tax filings as well as sales and use taxes.• Management sponsor and lead on the implementation of NetSuite ERP.• Board member of India and Philippines operations.

• Expatriate assignment located in the Manchester, United Kingdom (“UK”).• Manage the daily financial operations and close processes for 5 international entities in the UK (Omnicell Ltd. and Avantec Ltd.), Germany (Mach4 and Omnicell GmbH) and France (Omnicell SAS), including the coordination of quarterly and annual close reporting with Omnicell’s corporate offices in Mountain View, CA; Quarterly presentations to Executive Staff.• Manage and coordinate with corporate offices the requirements for purchase accounting of 3 acquisitions located in the UK (Surgichem, 2014; Avantec, 2015) and Germany (Mach4, including then subsidiaries in the UK and France, 2015) and 2 asset purchase transactions in France (EURAF and Sextant, 2016).• Manage the overall integration budget for the Surgichem acquisition, including working with operations to facilitate the relocation and integration of the Omnicell, Ltd. and Surgichem operations to the current Europe, Middle East and Africa (“EMEA”) headquarters in Manchester. Co-managed the integration budget for the Avantec and Mach4 acquisitions.• Responsible for the integration of financial accounting and reporting activities with each of the aforementioned acquisitions.• Directly participated in the implementation of SAP for the Surgichem, Mach4 and Omnicell SAS entities. • Manage the implementation of TM1 at international locations for purposes of transferring Financial Planning and Analysis (“FP&A”) functions to EMEA headquarters.• Manage EMEA FP&A function, including planning, actuals vs. plan analysis and overall international reporting.• Manage international staff of 21 in the UK, Germany and France, including 4 direct reports.

• Omnicell was $213M in revenues in 2009.• Manage the daily financial operations and close processes, including general ledger, revenue recognition, consolidations, credit and collections, accounts payable, payroll, tax, stock administration and internal audit. • Manage the company’s SEC filings, including the writing of the Management Discussion and Analysis (“MD&A”) and Business sections for the Forms 10-Q and 10-K. • Quarterly presentations to Executive Staff and Audit Committee of the Board of Directors (“BOD”)• Manage the evaluation of internal controls through internal audit and facilitated the remediation of identified material weaknesses and control deficiencies in support of Sarbanes-Oxley Section 404 (“SOX”) requirements.• Manage the tax function including quarterly provisions, tax filings, R&D credits and transfer pricing studies.• Manage all aspects of the purchase accounting for the $156M acquisition of MTS Medication Technologies in 2012. • Manage a staff of 33 located in Mountain View, CA, St. Petersburg, FL, Germany and the UK, including 6 direct reports.

• Manage the daily financial operations and close processes, including general ledger, international subsidiary reporting, revenue recognition, collections, accounts payable, payroll, and stock administration. • Manage the quarterly reviews and annual audits; Quarterly presentations to the Audit Committee of the BOD.• Manage the company’s SEC filings, including the writing of the MD&A and Business sections for the Forms 10-Q and 10K; provide assistance in the generation of annual & special proxy filings.• Manage the evaluation of internal controls and the remediation of identified deficiencies in support of SOX requirements.• Work directly with FP&A team in generating plan vs. actual analytics for presentation to the BOD.• Provide quarterly reporting updates of 10-Q/10-K information and other special reports to the Audit Committee of the BOD.• Manage a staff of 10 with 3 direct reports

• Manage the daily financial operations and close processes, including general ledger, revenue recognition, consolidations, credit and collections, accounts payable, payroll, tax, stock administration and purchasing and receiving. • Manage all financial aspects in preparing the Form S-1 and Prospectus in preparation for a $40M IPO in July 2003.• Manage the company’s SEC filings, including the writing of the MD&A and Business sections for the Forms 10-Q and 10-K as well as completion of the Annual Proxy for the shareholder meetings. • Assisted the CFO with the budget process, updated forecasts and performed analysis against actuals.• Manage the evaluation of internal controls and the remediation of identified material weaknesses and control deficiencies in support of SOX requirements.• Work with outside tax consultants to complete quarterly provisions, tax filings, R&D credits and transfer pricing studies.• Oversee and guide the Oracle implementation.• Manage purchase accounting in 2005 for the acquisition of ULEAD Systems, a publicly traded Taiwan entity. • Manage a staff of 20 with 4 direct reports.

Controllership

Various